Myocardial Necrosis
Myocardial Necrosis - Related Videos
01:16
Necrosis
0 Views •
2023
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”. Morphological Manifestations of Necrosis Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
02:12
Muscle Necrosis Assay in C. elegans Induced by a Pathogenic Aeromonas Strain
0 Views •
2026
Source: Chen, Y. et. al., Evaluating Virulence and Pathogenesis of Aeromonas Infection in a Caenorhabditis elegans Model. J. Vis. Exp. (2018)This video demonstrates a muscle necrosis assay in C. elegans (Caenorhabditis elegans) using pathogenic Aeromonas strains. By feeding green fluorescent protein (GFP)-expressing worms on Aeromonas-seeded plates, the assay models bacterial infection and reveals tissue damage through fluorescence imaging. The progressive loss of muscle structure and GFP...
01:16
Cellular Injury IV: Necrosis
0 Views •
2026
Necrosis is a form of irreversible cell death caused by severe injury such as ischemia, toxins, or trauma. Unlike programmed cell death, it is an uncontrolled, pathological process that typically provokes inflammation in surrounding tissues.Pathophysiologic ChangesNecrosis begins when cells sustain critical damage, leading to swelling of organelles, particularly mitochondria, and rapid ATP depletion. As energy levels decline, membrane ion pumps fail, leading to calcium influx and eventually,...
07:45
Acute Myocardial Infarction in Rats
0 Views •
Cited by 103 •
2011
The rat model of acute myocardial infarction (AMI) is useful to study the consequence of a MI on cardiac pathophysiological and physiological function.
08:23
LAD-Ligation: A Murine Model of Myocardial Infarction
0 Views •
Cited by 81 •
2009
This video demonstrates how to use a fast and reliable model to study pathobiological and pathophysiological processes of myocardial ischemia.
FAQs
Severe ischemia restricts oxygen delivery to cardiomyocytes, reducing ATP production. As energy availability falls, the cells lose control of ion balance, which disrupts cellular membranes. Membrane damage allows intracellular proteins, including cardiac troponins, to escape into the circulation. These linked events connect oxygen deprivation with both measurable cardiac injury and the subsequent inflammatory response.
Cardiac troponins are intracellular proteins released when damaged cardiomyocyte membranes lose their integrity. Their presence provides a biochemical signal that heart muscle injury has occurred, allowing clinicians to evaluate necrotic damage together with electrocardiography and cardiac imaging. This combined assessment is more informative than relying on a single type of evidence when identifying cardiac injury.
Necrotic cardiomyocytes do more than release measurable proteins; their damage also triggers an inflammatory response. This response is part of the biological context surrounding cardiac injury and helps explain why researchers examine necrosis together with repair and adverse remodeling. Understanding that relationship supports efforts to limit harmful structural consequences after ischemic injury.
Clinical assessment combines cardiac troponin measurements with electrocardiography and cardiac imaging. Troponins provide evidence associated with damaged heart muscle, while the electrical and imaging assessments contribute complementary information about the cardiac event. Using these approaches together helps clinicians identify and assess necrotic injury rather than interpreting a laboratory finding in isolation.
Biomarker testing can reveal the release of intracellular cardiac proteins from injured cardiomyocytes, particularly cardiac troponins. Clinicians use this information to help identify necrotic injury and assess its extent, alongside electrocardiography and cardiac imaging. The value of testing therefore lies in its integration with other clinical assessments, not in treating the biomarker result as a standalone conclusion.
Research extends beyond recognizing necrosis during myocardial infarction because investigators also examine its causes, extent, and repair. These studies aim to improve diagnosis, limit adverse remodeling, and guide therapies for ischemic heart disease. Myocardial necrosis therefore serves as both a marker of cardiac injury and a target for understanding recovery and treatment development.